Evidence map›Paper›PMID 38606665›Full record

ArticleActa crystallographica. Section D, Structural biology2024

HEIDI: an experiment-management platform enabling high-throughput fragment and compound screening.

A Metz, D P Stegmann, E H Panepucci, S Buehlmann, C Y Huang, K E McAuley, M Wang, J A Wojdyla, M E Sharpe, K M L Smith

Abstract read
In one paragraph

Article in Acta crystallographica. Section D, Structural biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

A MetzSwiss Light Source, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.
D P StegmannSwiss Light Source, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.
E H PanepucciSwiss Light Source, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.
S BuehlmannSwiss Light Source, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.
C Y HuangSwiss Light Source, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.ORCID 0000-0002-7676-0239
K E McAuleySwiss Light Source, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.ORCID 0000-0002-9545-072X
M WangSwiss Light Source, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.ORCID 0000-0002-5340-3036
J A WojdylaSwiss Light Source, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.ORCID 0000-0002-8975-4137
M E SharpeSwiss Light Source, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.
K M L SmithSwiss Light Source, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland.ORCID 0000-0002-1183-8832

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Swiss Light Source facilitates fragment-based drug-discovery campaigns for academic and industrial users through the Fast Fragment and Compound Screening (FFCS) software suite. This framework is further enriched by the option to utilize the Smart Digital User (SDU) software for automated data collection across the PXI, PXII and PXIII beamlines. In this work, the newly developed HEIDI webpage (https://heidi.psi.ch) is introduced: a platform crafted using state-of-the-art software architecture and web technologies for sample management of rotational data experiments. The HEIDI webpage features a data-review tab for enhanced result visualization and provides programmatic access through a representational state transfer application programming interface (REST API). The migration of the local FFCS MongoDB instance to the cloud is highlighted and detailed. This transition ensures secure, encrypted and consistently accessible data through a robust and reliable REST API tailored for the FFCS software suite. Collectively, these advancements not only significantly elevate the user experience, but also pave the way for future expansions and improvements in the capabilities of the system.

Indexed as

Drug DiscoveryHigh-Throughput Screening AssaysSoftwareCrystallography, X-RaySmall Molecule LibrariesUser-Computer InterfaceSmall Molecule Librariesdata managementFFCS software suitefragment screeningHEIDIhigh-throughput crystallographysoftware

Identifiers

PMID38606665
PMCPMC11066879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.